INVO Fertility, Inc. (IVF): Entry into a Material Definitive Agreement
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ex10-1.htm EX-10.1 Exhibit 10.1 ANY MARKET PURCHASE AGREEMENT This Any Market Purchase Agreement (this “ Agreement ”), dated as of July 24, 2026 (the “ Execution Date ”), by and between INVO Fertility, Inc. , a Nevada corporation (the “ Company ”), and Alumni Capital LP
How this was made
The 30-second read
Why it matters
The agreement authorizes sales of common stock to the investor up to a stated maximum, which can translate into incremental share issuance as purchase notices are delivered.
Market read
This is a fresh capital-raising disclosure that can affect valuation via expected dilution and can drive trading volatility as investors price the facility’s drawdown path.
What to watch
Traders should focus on the purchase price mechanics, any discount/cap, daily volume limits, and whether the company can terminate early, since those determine realized dilution and timing.
Background
The 8-K reports entry into a material definitive agreement (Item 1.01) and includes Exhibit 10.1 for an “Any Market Purchase Agreement” with an investor.
Ticker impact
INVO Fertility entered a material definitive agreement to sell up to $50M of common stock to Alumni Capital under an “any market purchase” structure.
Near-term volatility possible, with downside risk if investors view the facility as dilutive; magnitude depends on how quickly shares are purchased and at what prices.
An 8-K Exhibit 10.1 describes a committed purchase capacity ($15M commitment, up to $50M) but the excerpt does not include key economic terms (purchase price formula, limits, and timing of drawdowns). That limits precision on dilution and immediate price impact.
Market effects
Adds another example of small-cap biotech using equity purchase facilities, which can reinforce sector-wide dilution concerns during risk-off tape.
No clear regional spillover beyond US small-cap healthcare equities.
Limited global relevance; primarily affects the issuer’s capital structure and trading liquidity.
Counterpoint
If the facility is used opportunistically at favorable prices or replaces more expensive financing, the net impact could be less dilutive than feared.
Key entities
- issuerINVO Fertility, Inc.
Company entering the equity purchase agreement disclosed in the 8-K.
- investorAlumni Capital LP
Counterparty investor purchasing common shares under the agreement.
